Zealand Pharma (ZEAL) to Ring the NASDAQ Stock Market Opening Bell

ADVISORY, June 2, 2011 (GLOBE NEWSWIRE) --

What:

Zealand Pharma, a biopharmaceutical company based in Copenhagen, Denmark with a mature and growing pipeline of novel peptide drugs, will visit the NASDAQ MarketSite in New York City's Times Square.

In honor of the occasion, David Solomon, President and Chief Executive Officer of Zealand Pharma, will ring the Opening Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Friday, June 3rd, 2011 – 09:15 - 09:30 ET (15:15 – 15:30 CEST)

Contact:

Zealand Pharma A/S

David Solomon, President and Chief Executive Officer

Tel: +45 4328 1200

Hanne Leth Hillman, Vice President for IR & Corporate Communications

Mobile: +45 5060 3689

NASDAQ MarketSite

Jen Knapp

(212) 401-8916

Jennifer.knapp@nasdaqomx.com

Feed Information:

The Opening Bell is available from 9:20 a.m. to 9:35 a.m. on AMC3 / C20, downlink frequency 4100 vertical. The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Jen Knapp at (212) 401-8916.

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/nasdaqomx                                  

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx

Webcast:

A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx or http://social.nasdaqomx.com.

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Zealand Pharma:

Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and growing pipeline of novel peptide drugs. The company's lead product candidate is Lyxumia® (lixisenatide), a once-daily GLP-1 completing Phase III development for the treatment of Type 2 Diabetes under collaboration with Sanofi. Zealand Pharma also has other collaboration and licensing partnerships, including a license agreement with Helsinn Healthcare on a clinical stage GLP-2 drug for the treatment of Chemotherapy and Radiotherapy Induced Diarrhea.

Zealand Pharma has unique expertise in peptide discovery and optimization and specializes in the development of novel peptide drugs targeting disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. All of Zealand Pharma's product candidates have been identified through the company's own drug discovery activities. For more information please visit www.zealandpharma.com.

About NASDAQ OMX:

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx). 

-NDAQA-

In This Story

NDAQ